The Mechanism of the Suppressive Action of Bromocriptine on Adrenocorticotropin Secretion in Patients with Cushing′s Disease and Nelson′s Syndrome*
The DOI matches its Crossref record.
Abstract
The oral administration of 2.5 mg bromocriptine elicited a significant suppression of plasma ACTH and cortisol in 6 of 13 patients with untreated Cushing′s disease. In the responding patients, mean plasma ACTH levels were higher and pituitary tumor size was larger than in the nonresponders. In two patients with Nelson′s syndrome, plasma ACTH was diminished by 70% and 30%, respectively, from 4-6 h after 2.5 mg bromocriptine. In one patient with ectopic ACTH secretion from a bronchial carcinoid, plasma ACTH was suppressed by 32% from 3-5 h after 2.5 mg bromocriptine. The effects of bromocriptine and cyproheptadine on the secretion of ACTH from trypsin-dispersed tumor cells prepared from the ACTH-secreting rat pituitary tumor 7315a were investigated in vitro. Bromocriptine (1 µM) inhibited ACTH secretion by 40% (P < 0.01), while 1 JUM cyproheptadine inhibited ACTH secretion by 25% (P < 0.01). On the basis of 1) the direct effects of bromocriptine and cyproheptadine on ACTH secretion by rat pituitary tumor cells, 2) the suppressive effect of bromocriptine in a patient with ectopic ACTH secretion, and 3) the increasing sensitivity of ACTH secretion to bromocriptine with increasing pituitary tumor size, we suggest that one mechanism of action of bromocriptine is a direct effect on the ACTH-secreting pituitary microadenoma n patients with Cushing′s disease and Nelson′s syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Pivonello, R., De Martino, M. C., Cappabianca, P., De Leo, M., Faggiano, A., Lombardi, G., Hofland, L. J., Lamberts, S. W. J., & Colao, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1533 · Cited by 328
Self-citationDopamine Receptor Expression and Function in Corticotroph Pituitary Tumors
Pivonello, R., Ferone, D., de Herder, W. W., Kros, J. M., Del Basso De Caro, M. L., Arvigo, M., Annunziato, L., Lombardi, G., Colao, A., Hofland, L. J., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030837 · Cited by 271
Self-citationCabergoline monotherapy in the long-term treatment of Cushing's disease
Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O. D., & Lacroix, A. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0382 · Cited by 202
Pivonello, R., De Martino, M. C., De Leo, M., Lombardi, G., & Colao, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.010 · Cited by 195
Neurobiological and neuroendocrine functions of the vasoactive intestinal peptide (vip)
ROSTENE, W. (1984) · Progress in Neurobiology · doi:10.1016/0301-0082(84)90022-4 · Cited by 183
Engler, D., Redei, E., & Kola, I. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0376 · Cited by 79
Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors
Pivonello, R., Ferone, D., de Herder, W. W., Faggiano, A., Bodei, L., de Krijger, R. R., Lombardi, G., Colao, A., Lamberts, S. W. J., & Hofland, L. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0728 · Cited by 68
“Furthermore, despite the demonstrated DA effectiveness in the treatment of pituitary-dependent CS (6, 19), the possible DA effectiveness in the treatment of EAS has never been tested.”
BackgroundSelf-citation
Metadata
- Authors
- LAMBERTS, S. W. J., KLIJN, J. G. M., DE QUIJADA, M., TIMMERMANS, H. A. T., UITTERLINDEN, P., DE JONG, F. H., & BIRKENHAGER, J. C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1980-08
- Volume
- 51
- Issue
- 2
- Pages
- 307-311
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1965731442
- Cited by
- 128
- References
- 0
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.